J&J Invests $55B in U.S. Manufacturing Expansion Amid Pharma Reshoring Trend

Johnson & Johnson announced a $55 billion investment to expand U.S. manufacturing, research, and technology over the next four years. The initiative includes three new advanced manufacturing facilities and expanding existing pharmaceutical and medical technology sites, with a 500,000-square-foot biologics plant already underway in North Carolina. This move follows similar commitments from industry giants Eli Lilly, Merck, and Amgen, as pharmaceutical companies aim to mitigate tariff risks and secure potential tax incentives.

The expansion represents a 25% increase in J&J’s capital expenditures compared to the past four years, reinforcing its commitment to domestic growth. With demand surging for its biologic medicines, the company seeks to enhance production capacity while benefiting from favorable corporate tax policies. The North Carolina facility is expected to create 5,000 construction jobs and 500 permanent positions, with further upcoming site announcements. J&J estimates its total economic impact in the U.S. exceeds $100 billion annually.